| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aripiprazole (Abilify) for schizophrenia. The Medical letter on drugs and therapeutics. vol 45. issue 1150. 2003-03-20. PMID:12592215. |
aripiprazole (abilify) for schizophrenia. |
2003-03-20 |
2023-08-12 |
Not clear |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
otsuka pharmaceuticals in collaboration with bristol-myers squibb is developing aripiprazole, a dual dopamine autoreceptor agonist and postsynaptic d2 receptor antagonist, for the potential treatment of psychoses including schizophrenia [281327], [340364]. |
2002-12-17 |
2023-08-12 |
Not clear |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
moreover, the mechanism of action of aripiprazole differentiates it from both typical and atypical antipsychotics and hence, may provide important leads for pharmacotherapy of schizophrenia and other psychotic disorders. |
2002-12-17 |
2023-08-12 |
Not clear |
| John M Kane, William H Carson, Anutosh R Saha, Robert D McQuade, Gary G Ingenito, Dan L Zimbroff, Mirza W Al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry. vol 63. issue 9. 2002-10-11. PMID:12363115. |
efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. |
2002-10-11 |
2023-08-12 |
Not clear |
| John M Kane, William H Carson, Anutosh R Saha, Robert D McQuade, Gary G Ingenito, Dan L Zimbroff, Mirza W Al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry. vol 63. issue 9. 2002-10-11. PMID:12363115. |
aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile. |
2002-10-11 |
2023-08-12 |
Not clear |
| Fuji Yokoi, Gerhard Gründer, Kathleen Biziere, Massoud Stephane, Ahmet S Dogan, Robert F Dannals, Hayden Ravert, Ajit Suri, Steven Bramer, Dean F Won. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 2. 2002-08-07. PMID:12093598. |
this underlines aripiprazole's unique mechanism of action as a partial dopamine receptor agonist, which might become a novel principle in the treatment of schizophrenia. |
2002-08-07 |
2023-08-12 |
human |
| J M Cañive, J D Lewine, J C Edgar, J T Davis, G A Miller, F Torres, V B Tuaso. Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacology bulletin. vol 34. issue 1. 1998-05-21. PMID:9580382. |
spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. |
1998-05-21 |
2023-08-12 |
human |
| J M Cañive, J D Lewine, J C Edgar, J T Davis, G A Miller, F Torres, V B Tuaso. Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacology bulletin. vol 34. issue 1. 1998-05-21. PMID:9580382. |
the schizophrenia subjects underwent a second meg recording after 8 weeks of open-label treatment with aripiprazole. |
1998-05-21 |
2023-08-12 |
human |